Identification

Name
Levorphanol
Accession Number
DB00854  (APRD00764)
Type
Small Molecule
Groups
Approved
Description

A narcotic analgesic that may be habit-forming. It is nearly as effective orally as by injection.

Structure
Thumb
Synonyms
  • Levorfanol
  • Levorfanolo
  • Lévorphanol
  • Levorphanol
  • Levorphanolum
External IDs
Dea No. 9220 / Dea No. 9733 / IDS-NL-007 / RO 1-5431
Product Ingredients
IngredientUNIICASInChI Key
Levorphanol tartrate04WQU6T9QINot AvailableUMZNDVASJKIQCB-QLFXFZCRSA-N
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Levorphanol TartrateTablet2 mg/1OralRoxane Laboratories2000-03-31Not applicableUs
Levorphanol TartrateTablet2 mg/1OralSentynl Therapeutics, Inc.2015-05-28Not applicableUs
International/Other Brands
Aromarone / Cetarin / Lemoran / Levo-Dromoran (Valeant Pharmaceuticals International)
Categories
UNII
27618J1N2X
CAS number
77-07-6
Weight
Average: 257.3706
Monoisotopic: 257.177964363
Chemical Formula
C17H23NO
InChI Key
JAQUASYNZVUNQP-USXIJHARSA-N
InChI
InChI=1S/C17H23NO/c1-18-9-8-17-7-3-2-4-14(17)16(18)10-12-5-6-13(19)11-15(12)17/h5-6,11,14,16,19H,2-4,7-10H2,1H3/t14-,16+,17+/m0/s1
IUPAC Name
(1R,9R,10R)-17-methyl-17-azatetracyclo[7.5.3.0¹,¹⁰.0²,⁷]heptadeca-2(7),3,5-trien-4-ol
SMILES
[H][C@@]12CCCC[C@@]11CCN(C)[C@@H]2CC2=C1C=C(O)C=C2

Pharmacology

Indication

For the management of moderate to severe pain or as a preoperative medication where an opioid analgesic is appropriate.

Structured Indications
Pharmacodynamics

Levorphanol is a potent synthetic opioid analgesic indicated for the management of moderate to severe pain or as a preoperative medication where an opioid analgesic is appropriate. Levorphanol is similar to morphine in its actions, however it is up to 8 times more potent than morphine. Levorphanol produces a degree of respiratory depression similar to that produced by morphine at equianalgesic doses, and like many mu-opioid drugs, levorphanol produces euphoria or has a positive effect on mood in many individuals.

Mechanism of action

Like other mu-agonist opioids it is believed to act at receptors in the periventricular and periaqueductal gray matter in both the brain and spinal cord to alter the transmission and perception of pain.

TargetActionsOrganism
AMu-type opioid receptor
agonist
Human
UDelta-type opioid receptor
agonist
Human
UKappa-type opioid receptor
agonist
Human
Absorption

Levorphanol is well absorbed after PO administration with peak plasma concentrations occurring approximately 1 hour after dosing.

Volume of distribution
  • 10 to 13 L/kg
Protein binding

40%

Metabolism

Levorphanol is extensively metabolized in the liver and is eliminated as the glucuronide metabolite.

Route of elimination
Not Available
Half life

11-16 hours

Clearance
  • 0.78 to 1.1 L/kg/hr
Toxicity

LD50=150 mg/kg (orally in rats). Signs of overdose include nausea, emesis, dizziness, respiratory depression, hypotension, urinary retention, cardiac arrhythmias, allergic reactions, skin rash, and uticaria.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Levorphanol Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Levorphanol.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Levorphanol.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Levorphanol.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Levorphanol is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Levorphanol is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Acetazolamide.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Levorphanol.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Levorphanol is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Agomelatine.Approved, Investigational
AlaproclateLevorphanol may increase the serotonergic activities of Alaproclate.Experimental
AlcuroniumThe risk or severity of adverse effects can be increased when Alcuronium is combined with Levorphanol.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Levorphanol.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Levorphanol.Approved, Vet Approved
AllopregnanoloneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Levorphanol.Approved, Illicit, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Levorphanol is combined with Alvimopan.Approved
AmilorideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Amiloride.Approved
AmisulprideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Amitriptyline.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Levorphanol which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Levorphanol is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Levorphanol.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Levorphanol.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Levorphanol is combined with Aripiprazole.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Asenapine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Atracurium is combined with Levorphanol.Experimental
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Levorphanol.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Levorphanol.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Azaperone.Vet Approved
AzelastineLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Levorphanol is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Levorphanol is combined with Barbital.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Levorphanol.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Levorphanol is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Levorphanol.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Benzocaine.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Levorphanol.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Levorphanol is combined with Benzyl alcohol.Approved
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Levorphanol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Levorphanol.Investigational
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Levorphanol.Experimental
BrexpiprazoleThe risk or severity of adverse effects can be increased when Levorphanol is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Bromazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Levorphanol is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Brotizolam.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Bupivacaine.Approved, Investigational
BuprenorphineLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Levorphanol.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Levorphanol.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Levorphanol is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Levorphanol is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Levorphanol is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Levorphanol.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Levorphanol is combined with Canertinib.Investigational
Canrenoic acidThe risk or severity of adverse effects can be increased when Levorphanol is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Canrenone.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Levorphanol.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Levorphanol is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Caroxazone.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Levorphanol.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chloroprocaine.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Levorphanol.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Levorphanol.Illicit, Withdrawn
ChlorproethazineChlorproethazine may increase the hypotensive activities of Levorphanol.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Levorphanol.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chlorzoxazone.Approved
CicletanineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Cicletanine.Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Cinchocaine.Approved, Vet Approved
CitalopramLevorphanol may increase the serotonergic activities of Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Levorphanol is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Clobazam.Approved, Illicit
ClofenamideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Clofenamide.Experimental
clomethiazoleThe risk or severity of adverse effects can be increased when Levorphanol is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Clonidine.Approved
ClopamideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Clopamide.Experimental
ClopenthixolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levorphanol.Approved, Illicit
ClorexoloneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Clorexolone.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Levorphanol.Approved
CocaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Levorphanol.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Levorphanol is combined with Conivaptan.Approved, Investigational
CyclizineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Cyclobenzaprine.Approved
CyclopenthiazideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Cyclopenthiazide.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Levorphanol.Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dapiprazole.Approved
DapoxetineLevorphanol may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Levorphanol.Approved, Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Levorphanol is combined with Desmopressin.Approved
DesvenlafaxineLevorphanol may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Levorphanol.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Levorphanol.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Levorphanol.Approved, Illicit, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Levorphanol.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Levorphanol is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may increase the analgesic activities of Levorphanol.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Levorphanol is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Levorphanol is combined with Diphenoxylate.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Levorphanol is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Levorphanol is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Levorphanol is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Drotebanol.Experimental, Illicit
DuloxetineLevorphanol may increase the serotonergic activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Levorphanol is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Efonidipine.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Eltanolone.Investigational
EluxadolineLevorphanol may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Levorphanol.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Enflurane.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Levorphanol is combined with Entacapone.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Eplerenone.Approved
EscitalopramLevorphanol may increase the serotonergic activities of Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Levorphanol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Levorphanol is combined with Etacrynic acid.Approved
EtanautineThe risk or severity of adverse effects can be increased when Etanautine is combined with Levorphanol.Experimental
EthanolLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Levorphanol.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ethyl chloride.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Levorphanol is combined with Etomidate.Approved
EtoperidoneLevorphanol may increase the serotonergic activities of Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Etybenzatropine is combined with Levorphanol.Experimental
EzogabineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Levorphanol is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenquizoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fenquizone.Experimental
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Levorphanol.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Levorphanol.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Levorphanol is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Flunitrazepam.Approved, Illicit
FluoxetineLevorphanol may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Levorphanol.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Levorphanol.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fluspirilene.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fospropofol.Approved, Illicit
FurazolidoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Furazolidone.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Levorphanol is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Levorphanol is combined with Gabapentin Enacarbil.Approved
GallamineThe risk or severity of adverse effects can be increased when Gallamine is combined with Levorphanol.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Levorphanol.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Levorphanol is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GepefrineGepefrine may increase the analgesic activities of Levorphanol.Experimental
GepironeThe risk or severity of adverse effects can be increased when Levorphanol is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Glutethimide.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Levorphanol.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Levorphanol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Levorphanol is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Levorphanol.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Levorphanol is combined with Hexobarbital.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Levorphanol.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Hydracarbazine.Experimental
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Levorphanol.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may increase the analgesic activities of Levorphanol.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Levorphanol.Approved
IbopamineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ibopamine.Experimental
IloperidoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Imipramine.Approved
IndalpineLevorphanol may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Indapamide.Approved
IndiplonThe risk or severity of adverse effects can be increased when Levorphanol is combined with Indiplon.Investigational
Iofetamine I-123Iofetamine I-123 may increase the analgesic activities of Levorphanol.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Levorphanol.Approved
IproclozideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Levorphanol is combined with Iproniazid.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Levorphanol is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Levorphanol.Approved, Vet Approved
IsosorbideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Isosorbide.Approved
KetamineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ketobemidone.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levorphanol is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levorphanol is combined with Levomethadyl Acetate.Approved
LevomilnacipranLevorphanol may increase the serotonergic activities of Levomilnacipran.Approved
LidocaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Lidocaine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Levorphanol.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Levorphanol is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Levorphanol is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Levorphanol.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Levorphanol.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Maprotiline.Approved
MazaticolThe risk or severity of adverse effects can be increased when Mazaticol is combined with Levorphanol.Experimental
MebanazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Levorphanol is combined with Mebicar.Experimental
MebutizideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Mebutizide.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Levorphanol.Approved
MeclizineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Medetomidine.Vet Approved
MefrusideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Mefruside.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Levorphanol is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Melperone.Approved
MephedroneMephedrone may increase the analgesic activities of Levorphanol.Investigational
MephentermineMephentermine may increase the analgesic activities of Levorphanol.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Levorphanol.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Meptazinol.Experimental
MersalylThe risk or severity of adverse effects can be increased when Levorphanol is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Levorphanol.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Levorphanol.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Levorphanol.Approved
MethapyrileneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Levorphanol.Approved
MethotrimeprazineLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methoxyflurane.Approved, Vet Approved
MethoxyphenamineMethoxyphenamine may increase the analgesic activities of Levorphanol.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methyclothiazide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methylecgonine.Experimental
Methylene blueMethylene blue may increase the hypotensive activities of Levorphanol.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methylphenobarbital.Approved
MeticraneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Meticrane.Experimental
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Levorphanol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Metolazone.Approved
MetyrosineLevorphanol may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Levorphanol.Approved, Illicit
Midomafetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Levorphanol.Experimental, Illicit
MilnacipranLevorphanol may increase the serotonergic activities of Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.Approved, Investigational
MirtazapineLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAMMDA may increase the analgesic activities of Levorphanol.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Moclobemide.Approved
MolindoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Levorphanol.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Levorphanol.Approved, Investigational
MuzolimineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Muzolimine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Levorphanol.Approved
NaltrexoneThe therapeutic efficacy of Levorphanol can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NefazodoneLevorphanol may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NialamideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Nialamide.Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Nitrous oxide.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Nortriptyline.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Levorphanol is combined with Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Levorphanol.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Levorphanol is combined with Opium.Approved, Illicit
OrphenadrineLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Levorphanol is combined with Osanetant.Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Levorphanol.Experimental
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Levorphanol.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Oxethazaine.Investigational
OxitropiumThe risk or severity of adverse effects can be increased when Oxitropium is combined with Levorphanol.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Levorphanol is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Oxybuprocaine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Levorphanol.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Levorphanol.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Levorphanol.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Paliperidone.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Levorphanol.Approved
ParaldehydeLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pargyline.Approved
ParoxetineLevorphanol may increase the serotonergic activities of Paroxetine.Approved, Investigational
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Levorphanol.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Levorphanol.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Levorphanol.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Levorphanol.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.Approved
PerazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Levorphanol is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Levorphanol.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Levorphanol.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Phenelzine.Approved
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Levorphanol.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Levorphanol is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pheniprazine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Levorphanol is combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Phenoxypropazine.Withdrawn
PhenterminePhentermine may increase the analgesic activities of Levorphanol.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Levorphanol is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pipamperone.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Levorphanol.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pipotiazine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Levorphanol.Approved
PiretanideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pirlindole.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pomalidomide.Approved
PotassiumThe risk or severity of adverse effects can be increased when Levorphanol is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Levorphanol is combined with Potassium Citrate.Approved, Vet Approved
PramipexoleLevorphanol may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Levorphanol.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levorphanol.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Levorphanol.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Levorphanol.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Levorphanol is combined with Propanidid.Experimental
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Levorphanol.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Proparacaine.Approved, Vet Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Levorphanol.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Levorphanol.Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Levorphanol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Levorphanol is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Levorphanol is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Levorphanol.Approved
QuazepamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Quetiapine.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Quinethazone.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Levorphanol.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ramelteon.Approved, Investigational
RamosetronLevorphanol may increase the constipating activities of Ramosetron.Approved
RasagilineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Levorphanol is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Levorphanol.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Levorphanol.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Levorphanol.Investigational
RolofyllineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Rolofylline.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Romifidine.Vet Approved
RopiniroleLevorphanol may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ropivacaine.Approved
RotigotineLevorphanol may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Levorphanol.Approved
SafrazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Safrazine.Withdrawn
ScopolamineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Levorphanol.Approved, Vet Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Levorphanol.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Levorphanol is combined with Sertindole.Approved, Withdrawn
SertralineLevorphanol may increase the serotonergic activities of Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Sevoflurane.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Levorphanol.Approved
SpiradolineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Spiradoline.Investigational
SpironolactoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Spironolactone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Stiripentol.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Levorphanol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Levorphanol.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Sulpiride.Approved
SultoprideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Sultopride.Experimental
SuvorexantLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Levorphanol.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tetrodotoxin.Investigational
ThalidomideLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Theobromine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Levorphanol is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Levorphanol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Levorphanol.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Levorphanol is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Levorphanol.Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tiapride.Approved, Investigational
TicrynafenThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tilidine.Experimental
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Levorphanol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Toloxatone.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Levorphanol.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Levorphanol is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Levorphanol.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Trazodone.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Triazolam.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Levorphanol.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Levorphanol.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Levorphanol.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Triprolidine.Approved
TropatepineThe risk or severity of adverse effects can be increased when Tropatepine is combined with Levorphanol.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Levorphanol.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Levorphanol.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Levorphanol.Approved
UlaritideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ularitide.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Levorphanol is combined with Valproic Acid.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Levorphanol.Approved
VenlafaxineLevorphanol may increase the serotonergic activities of Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Levorphanol is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Levorphanol is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Levorphanol is combined with Xenon.Experimental
XipamideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Xipamide.Experimental
XylazineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Levorphanol is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ziconotide.Approved
ZimelidineLevorphanol may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Levorphanol.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Levorphanol is combined with Zolazepam.Vet Approved
ZolpidemLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Levorphanol is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Levorphanol is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Levorphanol is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals. Avoid alcohol.

References

Synthesis Reference

Joseph P. Haar, "Process for the Production of Levorphanol and Related Compounds." U.S. Patent US20080146805, issued June 19, 2008.

US20080146805
General References
Not Available
External Links
Human Metabolome Database
HMDB14992
KEGG Drug
D08123
KEGG Compound
C08014
PubChem Compound
5359272
PubChem Substance
46506558
ChemSpider
16736212
BindingDB
50017233
ChEBI
6444
ChEMBL
CHEMBL592
Therapeutic Targets Database
DAP000268
PharmGKB
PA164744368
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Levorphanol
ATC Codes
Not Available
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Download (5.23 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableCompletedNot AvailablePain, Chronic1

Pharmacoeconomics

Manufacturers
  • Valeant pharmaceuticals international
  • Roxane laboratories inc
Packagers
Dosage forms
FormRouteStrength
TabletOral2 mg/1
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)198-199 °CPhysProp
water solubility1840 mg/LNot Available
logP3.11HANSCH,C ET AL. (1995)
pKa9.58SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.173 mg/mLALOGPS
logP3.29ALOGPS
logP2.9ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)10.46ChemAxon
pKa (Strongest Basic)9.66ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area23.47 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity78.08 m3·mol-1ChemAxon
Polarizability29.84 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9924
Blood Brain Barrier+0.9953
Caco-2 permeable+0.8767
P-glycoprotein substrateSubstrate0.8217
P-glycoprotein inhibitor INon-inhibitor0.7866
P-glycoprotein inhibitor IINon-inhibitor0.935
Renal organic cation transporterInhibitor0.7666
CYP450 2C9 substrateNon-substrate0.7467
CYP450 2D6 substrateSubstrate0.78
CYP450 3A4 substrateSubstrate0.7112
CYP450 1A2 substrateNon-inhibitor0.6437
CYP450 2C9 inhibitorNon-inhibitor0.9139
CYP450 2D6 inhibitorInhibitor0.7703
CYP450 2C19 inhibitorNon-inhibitor0.8908
CYP450 3A4 inhibitorNon-inhibitor0.8856
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9051
Ames testNon AMES toxic0.5661
CarcinogenicityNon-carcinogens0.9694
BiodegradationNot ready biodegradable0.9681
Rat acute toxicity2.9455 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6841
hERG inhibition (predictor II)Non-inhibitor0.5153
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0a4i-5930000000-4593c62f1e2a0579a248
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Morphinans
Sub Class
Not Available
Direct Parent
Morphinans
Alternative Parents
Phenanthrenes and derivatives / Benzazocines / Tetralins / Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Piperidines / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds
show 1 more
Substituents
Morphinan / Phenanthrene / Benzazocine / Tetralin / 1-hydroxy-2-unsubstituted benzenoid / Aralkylamine / Piperidine / Benzenoid / Tertiary aliphatic amine / Tertiary amine
show 10 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
morphinane alkaloid (CHEBI:6444)

Targets

Details
1. Mu-type opioid receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Voltage-gated calcium channel activity
Specific Function
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name
OPRM1
Uniprot ID
P35372
Uniprot Name
Mu-type opioid receptor
Molecular Weight
44778.855 Da
References
  1. Allen RM, Granger AL, Dykstra LA: The competitive N-methyl-D-aspartate receptor antagonist (-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid (LY235959) potentiates the antinociceptive effects of opioids that vary in efficacy at the mu-opioid receptor. J Pharmacol Exp Ther. 2003 Nov;307(2):785-92. Epub 2003 Sep 15. [PubMed:12975489]
  2. Prommer E: Levorphanol: the forgotten opioid. Support Care Cancer. 2007 Mar;15(3):259-64. Epub 2006 Oct 13. [PubMed:17039381]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine n...
Gene Name
OPRD1
Uniprot ID
P41143
Uniprot Name
Delta-type opioid receptor
Molecular Weight
40368.235 Da
References
  1. Prommer E: Levorphanol: the forgotten opioid. Support Care Cancer. 2007 Mar;15(3):259-64. Epub 2006 Oct 13. [PubMed:17039381]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
Gene Name
OPRK1
Uniprot ID
P41145
Uniprot Name
Kappa-type opioid receptor
Molecular Weight
42644.665 Da
References
  1. Prommer E: Levorphanol: the forgotten opioid. Support Care Cancer. 2007 Mar;15(3):259-64. Epub 2006 Oct 13. [PubMed:17039381]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:47